These data suggest that ECM1 induces cancer cell stemness to confer cisplatin resistance through ABCG1-mediated upregulation of CD326, whereas treatment of CD326+ cells with a low dose of cisplatin significantly enriches the CD326+ cell population to enhance cancer cell stemness. The gene discussed is EPCAM; the disease is cancer.